Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, from 13:30 to 17:00 UK time at the London Stock Exchange. The event will be held in person and via live webcast, with in-person attendance by invitation only on a first-come, first-served basis. Details of how to access the live webcast are available here.
In addition, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November, providing further insight into the Company's new biosimilars development and supply-chain hub. Attendance will also be by invitation only on a first-come, first-served basis, and the event will not be webcasted.
The capital markets day comes as Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing, and 140 years of heritage in 2026. With net sales of USD 11.1 billion in 2025, the company is positioning itself to maximize value in what it calls its 'golden decade for biosimilars.' Biosimilars are lower-cost alternatives to biologic medicines, and Sandoz has been a key player in expanding patient access to these therapies globally.
The event is expected to provide investors with a deeper understanding of Sandoz's growth strategy, pipeline, and operational efficiencies. Given the increasing demand for affordable medicines and the expiration of patents on several blockbuster biologics, biosimilars represent a significant market opportunity. Sandoz's leadership in this space could translate into substantial revenue growth and cost savings for healthcare systems.
Forward-looking statements in the announcement highlight management's views and assumptions regarding future events and business performance, which are subject to risks and uncertainties. These include global economic conditions, exchange rates, legal provisions, market conditions, and competitive activities. Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
The Slovenia site visit will showcase Sandoz's new biosimilars development and supply-chain hub, underscoring the company's commitment to innovation and manufacturing excellence. This investment is part of Sandoz's broader strategy to strengthen its position in the biosimilars market and ensure reliable supply of affordable medicines to patients worldwide.
With a portfolio of approximately 1,300 medicines addressing diseases from the common cold to cancer, Sandoz reaches over one billion patients annually, generating substantial global healthcare savings. The capital markets day and site visit offer a unique opportunity for stakeholders to engage directly with management and gain insights into the company's future direction.
